100.55BMarket Cap28.90P/E (TTM)
10.97High10.67Low1.13MlotVolume10.83Open10.87Pre Close1.22BTurnover1.43%Turnover Ratio29.94P/E (Static)9.33BShares20.6352wk High5.50P/B85.22BFloat Cap9.6752wk Low13.04Limit Up7.91BShs Float42.49Historical High8.70Limit Down2.76%Amplitude0.02Historical Low0.15Dividend TTM10.78Avg Price558.90KlotAsk1.39%Div YieldTTM100Lot Size530.14KlotBid
Aier Eye Hospital Group Stock Forum
UOBKH: Healthcare – China (Overweight) - Alpha Edge Investing
$WUXI BIO(02269.HK)$ $WUXI APPTEC(02359.HK)$ $INNOVENT BIO(01801.HK)$ $VENUS MEDTECH-B(02500.HK)$ $HENLIUS(02696.HK)$ $Aier Eye Hospital Group(300015.SZ)$ $Shenzhen Mindray Bio-Medical Electronics(300760.SZ)$
UOBKH: Alpha Picks – July Conviction Calls (Greater China) - Alpha Edge Investing
$CG SERVICES(06098.HK)$ $LI AUTO-W(02015.HK)$ $Zhejiang Shuanghuan Driveline(002472.SZ)$ $LINK REIT(00823.HK)$ $GWMOTOR(02333.HK)$ $Aier Eye Hospital Group(300015.SZ)$ $ANTA SPORTS(02020.HK)$ $BYD COMPANY(01211.HK)$ $Contemporary Amperex Technology(300750.SZ)$ $CHINA OVERSEAS(00688.HK)$ $COSCO SHIP PORT(01199.HK)$ $Shenzhen Inovance Technology(300124.SZ)$ $BEKE-W(02423.HK)$ $KUAISHOU-W(01024.HK)$ $Kweichow Moutai(600519.SH)$ $TENCENT(00700.HK)$
UOB KH report.
MSCI China now trades at an undemanding 12-month forward PE of 10.2x, or a 37.0% discount to Emerging Asia. This steep discount is unwarranted and they expect valuation to normalise in 2H23, backed by additional policy support. However, a significant rerating is only possible if credit growth accelerates; hence, their index target is at 74 points for now, implying 12.0x target PE. They prefer exposure to automobiles, co...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
No comment yet